School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, City East Campus, G.P.O Box 2471, Adelaide, SA 5001, Australia.
Stem Cells Int. 2011;2011:570125. doi: 10.4061/2011/570125. Epub 2011 Jul 26.
In the last two decades, there has been a strong interest in searching for biological treatments for regeneration of injured growth plate cartilage and prevention of its bony repair. Various means have been tried, including implantation of chondrocytes, mesenchymal stem cell (MSC), together with exogenous growth factor and scaffolds, and gene therapy. However, with the lack of success with chondrocytes, more research has focussed on MSC-based treatments. In addition to circumvent limitations with MSC-based treatments (including cell harvest-associated morbidity, difficulties/time/cost involved in MSC isolation and ex vivo expansion, and potential disease transmission), mobilising endogenous MSCs to the growth plate injury site and enhancing in situ regeneration mechanisms would represent an alternative attractive approach. Further studies are required to investigate the potential particularly in large animal models or clinical setting of the ex vivo MSC approach and the feasibility of the endogenous MSC in situ approach in growth plate regeneration.
在过去的二十年中，人们对寻找生物治疗方法以促进受伤生长板软骨的再生和防止其骨修复产生了浓厚的兴趣。已经尝试了各种方法，包括植入软骨细胞、间充质干细胞（MSC），以及外源性生长因子和支架，还有基因治疗。然而，由于软骨细胞治疗效果不佳，更多的研究集中在基于 MSC 的治疗方法上。除了克服基于 MSC 的治疗方法的局限性（包括细胞采集相关的发病率、MSC 分离和体外扩增的困难/时间/成本，以及潜在的疾病传播），将内源性 MSC 动员到生长板损伤部位并增强原位再生机制将是一种有吸引力的替代方法。需要进一步的研究来探讨外源性 MSC 方法在大型动物模型或临床环境中的潜在应用，以及内源性 MSC 原位方法在生长板再生中的可行性。
